28 October 2020 - KYE Pharmaceuticals today announced an important milestone, Firdapse (amifampridine phosphate), the first amifampridine product approved in Canada, is now widely available for the treatment of Lambert-Eaton myasthenic syndrome in adults.

As part of that commitment, KYE is excited to introduce the Firdapse Patient Support Program comprehensively designed to assist patients in navigating prescription drug reimbursement, including facilitation of a smooth transition from their current amifampridine therapy (when needed), and providing any financial assistance that may be required to ensure timely access to therapy with Firdapse. Importantly, as Firdapse was also granted 8 years of data protection upon approval, patients on therapy with Firdapse are guaranteed access to their branded product throughout this time period without concern for generic substitution. No adult patient requiring treatment with Firdapse for Lambert-Eaton myasthenic syndrome will be without therapy.

Read KYE Pharmaceuticals press release